Vivani Medical (VANI) is trading 9.2% up at $1.42 in pre-market following news of a significant agreement. The company announced on July 7, 2026, that it has entered into an agreement with Novo Nordisk to evaluate NPM-139, its semaglutide implant for chronic weight management. * This non-exclusive deal supports Vivani's GLP-1 implant strategy and plans for an upcoming Phase 1 first-in-human trial. * The stock is extending a multi-day upward trend, with today's move attributed to this new corporate development.